(Q38042048)

27 August 2017

title

Targeting the Th17 pathway in psoriasis (English)

1 reference

27 August 2017

M Merle Elloso

1

1 reference

27 August 2017

Mireia Gomez-Angelats

series ordinal

2

1 reference

27 August 2017

Anne M Fourie

series ordinal

3

1 reference

27 August 2017

language of work or name

1 reference

7 September 2012

1 reference

Journal of Leukocyte Biology

27 August 2017

published in

1 reference

27 August 2017

volume

92

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

1187-1197

1 reference

IL-23 drives a pathogenic T cell population that induces autoimmune inflammation

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Mouse T helper 17 phenotype: not so different than in man after all.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

STAT3 regulates cytokine-mediated generation of inflammatory helper T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

T helper 17 lineage differentiation is programmed by orphan nuclear receptors ROR alpha and ROR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Structure and signalling in the IL-17 receptor family

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Identification of an interleukin 17F/17A heterodimer in activated human CD4+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Differential roles of interleukin-17A and -17F in host defense against mucoepithelial bacterial infection and allergic responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Regulation of inflammatory responses by IL-17F

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Innate IL-17-producing cells: the sentinels of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Molecular characterization of the human interleukin (IL)-17 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Cutting edge: interleukin 17 signals through a heteromeric receptor complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Identification of the IL-17 receptor related molecule IL-17RC as the receptor for IL-17F

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

The inducible kinase IKKi is required for IL-17-dependent signaling associated with neutrophilia and pulmonary inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-17E, a novel proinflammatory ligand for the IL-17 receptor homolog IL-17Rh1

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Interleukin-17C promotes Th17 cell responses and autoimmune disease via interleukin-17 receptor E.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-17C regulates the innate immune function of epithelial cells in an autocrine manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-17RE is the functional receptor for IL-17C and mediates mucosal immunity to infection with intestinal pathogens

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Circulating Th17, Th22, and Th1 cells are increased in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Chronically inflamed human tissues are infiltrated by highly differentiated Th17 lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-23 and IFN-gamma deficiency in immunodeficient HIV patients who achieved a long-term increase in CD4 T-cell counts on highly active antiretroviral therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

In vitro and in situ expression of IL-23 by keratinocytes in healthy skin and psoriasis lesions: enhanced expression in psoriatic skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Pivotal role of dermal IL-17-producing γδ T cells in skin inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Overrepresentation of IL-17A and IL-22 producing CD8 T cells in lesional skin suggests their involvement in the pathogenesis of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Mast cells express IL-17A in rheumatoid arthritis synovium

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Cutting edge: A critical functional role for IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Distinct roles of IL-23 and IL-17 in the development of psoriasis-like lesions in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

T helper 17 cell heterogeneity and pathogenicity in autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Psoriasis is characterized by accumulation of immunostimulatory and Th1/Th17 cell-polarizing myeloid dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

An anti-IL-12p40 antibody down-regulates type 1 cytokines, chemokines, and IL-12/IL-23 in psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Briakinumab for the treatment of plaque psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Effects of AIN457, a Fully Human Antibody to Interleukin-17A, on Psoriasis, Rheumatoid Arthritis, and Uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Ligand regulation of retinoic acid receptor-related orphan receptors: implications for development of novel therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Foxp3 inhibits RORgammat-mediated IL-17A mRNA transcription through direct interaction with RORgammat

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Isoform-specific amino-terminal domains dictate DNA-binding properties of ROR alpha, a novel family of orphan hormone nuclear receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORγt activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Ursolic acid suppresses interleukin-17 (IL-17) production by selectively antagonizing the function of RORgamma t protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Identification of SR2211: a potent synthetic RORγ-selective modulator.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Noncalcemic Actions of Vitamin D Receptor Ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Calcipotriol/betamethasone dipropionate: a review of its use in the treatment of psoriasis vulgaris of the trunk, limbs and scalp

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

1,25-dihydroxyvitamin D(3) ameliorates Th17 autoimmunity via transcriptional modulation of interleukin-17A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

1α,25-Dihydroxyvitamin D3 and all-trans retinoic acid synergistically inhibit the differentiation and expansion of Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Signal transduction pathways and transcriptional regulation in the control of Th17 differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

The JAK-STAT signaling pathway: input and output integration

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Janus kinases in immune cell signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Dynamics and non-canonical aspects of JAK/STAT signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Involvement of tyrosine kinase-2 in both the IL-12/Th1 and IL-23/Th17 axes in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Incyte comes of age with JAK inhibitor approval.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

A new orally active anti-rheumatic drug targets IL-15 and IL-17

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Selective abrogation of Th1 response by STA-5326, a potent IL-12/IL-23 inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Randomized, double-blind, placebo-controlled trial of the oral interleukin-12/23 inhibitor apilimod mesylate for treatment of active Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Crohn's disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Benefit-risk assessment of tumour necrosis factor antagonists in the treatment of psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

IL-17/Th17 targeting: on the road to prevent chronic destructive arthritis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Anti–Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1189%2FJLB.0212101

21 January 2018

Identifiers

DOI

10.1189/JLB.0212101

1 reference

27 August 2017

1 reference